|
US20030027216A1
(en)
|
2001-07-02 |
2003-02-06 |
Kiernan Urban A. |
Analysis of proteins from biological fluids using mass spectrometric immunoassay
|
|
EP1261620A2
(en)
|
2000-02-07 |
2002-12-04 |
Roche Diagnostics Corporation |
Cationic amphiphiles for use in nucleic acid transfection
|
|
US20070026394A1
(en)
|
2000-02-11 |
2007-02-01 |
Lawrence Blatt |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
|
|
US20030072794A1
(en)
|
2000-06-09 |
2003-04-17 |
Teni Boulikas |
Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
|
|
RU2322500C2
(ru)
|
2000-12-01 |
2008-04-20 |
Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. |
Малые молекулы рнк, опосредующие интерференцию рнк
|
|
WO2002059621A2
(en)
|
2001-01-24 |
2002-08-01 |
Bayer Corporation |
Regulation of transthyretin to treat obesity
|
|
US20030170891A1
(en)
|
2001-06-06 |
2003-09-11 |
Mcswiggen James A. |
RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
AU2002318396A1
(en)
|
2001-06-21 |
2003-01-08 |
The Cleveland Clinic Foundation |
Homocysteinylated transthyretin
|
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
|
ES2280826T5
(es)
|
2002-08-05 |
2017-08-03 |
Silence Therapeutics Gmbh |
Nuevas formas adicionales de moléculas de ARN de interferencia
|
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
JP2006504971A
(ja)
|
2002-11-01 |
2006-02-09 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト |
マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
DK2284266T3
(da)
|
2002-11-14 |
2014-01-13 |
Thermo Fisher Scient Biosciences Inc |
sIRNA-MOLEKYLE MOD TP53
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
EP3450559A1
(en)
|
2003-03-07 |
2019-03-06 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
|
EP1608735A4
(en)
|
2003-04-03 |
2008-11-05 |
Alnylam Pharmaceuticals |
RNAI CONJUGATES
|
|
SG190613A1
(en)
|
2003-07-16 |
2013-06-28 |
Protiva Biotherapeutics Inc |
Lipid encapsulated interfering rna
|
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
|
CA2568735A1
(en)
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
JP4764426B2
(ja)
|
2004-06-07 |
2011-09-07 |
プロチバ バイオセラピューティクス インコーポレイティッド |
カチオン性脂質および使用方法
|
|
AU2005252273B2
(en)
|
2004-06-07 |
2011-04-28 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
|
US7838561B2
(en)
|
2004-06-14 |
2010-11-23 |
Wisconsin Alumni Research Foundation |
Method for preventing or treating cardiac hypertrophy
|
|
SG144145A1
(en)
|
2004-12-08 |
2008-07-29 |
Sirion Therapeutics Inc |
Methods, assays and compositions for treating retinol-related diseases
|
|
WO2007086883A2
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
US7427605B2
(en)
|
2005-03-31 |
2008-09-23 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
|
US7915230B2
(en)
|
2005-05-17 |
2011-03-29 |
Molecular Transfer, Inc. |
Reagents for transfection of eukaryotic cells
|
|
JP5639338B2
(ja)
|
2005-07-27 |
2014-12-10 |
プロチバ バイオセラピューティクス インコーポレイティッド |
リポソームの製造システムおよび製造方法
|
|
US8101741B2
(en)
|
2005-11-02 |
2012-01-24 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
WO2007115168A2
(en)
|
2006-03-31 |
2007-10-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
CA2927045A1
(en)
|
2006-10-03 |
2008-04-10 |
Muthiah Manoharan |
Lipid containing formulations
|
|
GB0704764D0
(en)
|
2007-03-12 |
2007-04-18 |
Electrophoretics Ltd |
Isobarically labelled reagents and methods of their use
|
|
WO2009002944A1
(en)
|
2007-06-22 |
2008-12-31 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
EP3705125B1
(en)
|
2007-12-04 |
2023-07-05 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
CA2710713C
(en)
|
2007-12-27 |
2017-09-19 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
|
US20110117125A1
(en)
|
2008-01-02 |
2011-05-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for the delivery of nucleic acids
|
|
EP2245039A4
(en)
|
2008-01-31 |
2012-06-06 |
Alnylam Pharmaceuticals Inc |
OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN
|
|
US20100323381A1
(en)
|
2008-02-08 |
2010-12-23 |
Bergen Iii Harold R |
Classifying amyloidosis
|
|
US8058069B2
(en)
|
2008-04-15 |
2011-11-15 |
Protiva Biotherapeutics, Inc. |
Lipid formulations for nucleic acid delivery
|
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
|
WO2010017509A1
(en)
|
2008-08-07 |
2010-02-11 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression for the treatment of cns related disorders
|
|
WO2010042877A1
(en)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
HRP20150796T1
(hr)
|
2008-10-20 |
2015-09-11 |
Alnylam Pharmaceuticals, Inc. |
Pripravci i postupci za inhibiciju ekspresije transtiretina
|
|
MX353900B
(es)
|
2008-11-07 |
2018-02-01 |
Massachusetts Inst Technology |
Lipidoides de aminoalcohol y usos de los mismos.
|
|
CN105152939A
(zh)
|
2008-11-10 |
2015-12-16 |
阿尔尼拉姆医药品有限公司 |
用于递送治疗剂的脂质和组合物
|
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
KR20210031549A
(ko)
|
2009-05-05 |
2021-03-19 |
알닐람 파마슈티칼스 인코포레이티드 |
지질 조성물
|
|
KR20230098713A
(ko)
|
2009-06-10 |
2023-07-04 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
|
EP2442792A4
(en)
|
2009-06-15 |
2015-12-23 |
Alnylam Pharmaceuticals Inc |
TESTING GENE PCSK9 LIPID-FORMULATED DSRNA
|
|
JP5723378B2
(ja)
|
2009-11-03 |
2015-05-27 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
トランスサイレチン（ｔｔｒ）を阻害する脂質製剤化組成物及び方法
|
|
JP5860029B2
(ja)
|
2010-03-29 |
2016-02-16 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
トランスチレチン（ＴＴＲ）関連眼アミロイドーシスのためのｓｉＲＮＡ療法
|
|
US20230340473A1
(en)
|
2010-03-29 |
2023-10-26 |
Alnylam Pharmaceuticals, Inc. |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
|
NZ603339A
(en)
|
2010-04-29 |
2015-01-30 |
Isis Pharmaceuticals Inc |
Modulation of transthyretin expression
|
|
EP2616543A1
(en)
|
2010-09-15 |
2013-07-24 |
Alnylam Pharmaceuticals, Inc. |
MODIFIED iRNA AGENTS
|
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
|
CN103370054A
(zh)
|
2010-11-09 |
2013-10-23 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
|
CA2839896A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
MY167390A
(en)
*
|
2011-11-18 |
2018-08-16 |
Alnylam Pharmaceuticals Inc |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
|
KR20250133484A
(ko)
*
|
2011-11-18 |
2025-09-05 |
알닐람 파마슈티칼스 인코포레이티드 |
변형된 ＲＮＡｉ 제제
|
|
WO2013166041A1
(en)
|
2012-05-01 |
2013-11-07 |
The Trustees Of Columbia University In The City Of New York |
Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
|
|
EP2880162B1
(en)
|
2012-08-03 |
2017-07-05 |
Alnylam Pharmaceuticals, Inc. |
Modified rnai agents
|
|
AR097738A1
(es)
*
|
2013-09-23 |
2016-04-13 |
Alnylam Pharmaceuticals Inc |
Métodos para tratar o prevenir enfermedades asociadas con la transtiretina (ttr)
|
|
WO2015085158A1
(en)
|
2013-12-06 |
2015-06-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna
|
|
KR102344559B1
(ko)
*
|
2013-12-12 |
2021-12-31 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 ｉＲＮＡ 조성물 및 이의 이용 방법
|
|
IL316808A
(en)
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
DK3185957T3
(da)
|
2014-08-29 |
2022-08-29 |
Alnylam Pharmaceuticals Inc |
Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
|
|
EP3221299A1
(en)
|
2014-11-21 |
2017-09-27 |
BSIM2 Biomolecular Simulations Lda. |
2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
|
|
ES2842300T3
(es)
*
|
2015-07-31 |
2021-07-13 |
Alnylam Pharmaceuticals Inc |
Composiciones de ARNi de transtiretina (TTR) y métodos para su uso para el tratamiento o la prevención de enfermedades asociadas con TTR
|
|
KR20190098181A
(ko)
|
2016-12-16 |
2019-08-21 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
|
MA50267A
(fr)
|
2017-09-19 |
2020-07-29 |
Alnylam Pharmaceuticals Inc |
Compositions et méthodes de traitement de l'amylose médiée par la transthyrétine (ttr)
|
|
CA3114396A1
(en)
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
EP4022062A1
(en)
|
2019-08-30 |
2022-07-06 |
Alnylam Pharmaceuticals, Inc. |
Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
|
|
EP4055165A1
(en)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
JP2023516748A
(ja)
|
2020-03-06 |
2023-04-20 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
トランスサイレチン（ｔｔｒ）の発現を阻害するための組成物および方法
|
|
WO2022235537A1
(en)
|
2021-05-03 |
2022-11-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
|
JP2024523000A
(ja)
|
2021-06-08 |
2024-06-25 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
シュタルガルト病及び／又は網膜結合タンパク質４（ｒｂｐ４）関連障害を治療又は予防するための組成物及び方法
|
|
MX2024001194A
(es)
|
2021-08-03 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) de transtiretina (ttr) y sus metodos de uso.
|